REFERENCES
- Jampol LM, Sieving PA, Pugh D, et al. Multiple evanescent white dot syndrome. I. Clinical findings. Arch Ophthalmol. 1984;102:671–674.
- Namalis N, Daily MJ. Multiple evanescent white-dot syndrome. A report of eight cases. Ophthalmology. 1987;94:1209–1212.
- Ie D, Glaser BM, Murphy RP, et al. Indocyanine green angiography in multiple evanescent white-dot syndrome. Am J Ophthalmol. 1994;117:7–12.
- Obana A, Kusumi M, Miki T. Indocyanine green angiographic aspects of multiple evanescent white dot syndrome. Retina. 1996;16:97–104.
- Dell’Omo R, Mantovani A, Wong R, et al. Natural evolution of fundus autofluorescence findings in multiple evanescent white dot syndrome: A long-term follow-up. Retina. 2010;30:1479–1487.
- Dell’Omo R, Pavesio CE. Multiple evanescent white dot syndrome (MEWDS). Int Ophthalmol Clin. 2012;52:221–228.
- Wyhinny GJ, Jackson JL, Jampol LM, et al. Subretinal neovascularization following multiple evanescent white-dot syndrome. Arch Ophthalmol. 1990;108:1384–1385.
- Callanan D, Gass JD. Multifocal choroiditis and choroidal neovascularization associated with the multiple evanescent white dot and acute idiopathic blind spot enlargement syndrome. Ophthalmology. 1992;99:1678–1685.
- Rouvas AA, Ladas ID, Papakostas TD, et al. Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to multiple evanescent white dot syndrome. Eur J Ophthalmol. 2007;17:996–999.
- Battaglia Parodi M, Iacono P, La Spina C, et al. Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis. Br J Ophthalmol. 2014;98:519–522.
- Rouvas A, Petrou P, Douvali M, et al. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina. 2011;31:871–879.
- Julián K, Terrada C, Fardeau C, et al. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: Long-term results. Acta Ophthalmol. 2011;89:179–184.
- Battaglia Parodi M, Iacono P, Verbraak FD, et al. Antivascular endothelial growth factors for inflammatory chorioretinal disorders. Dev Ophthalmol. 2010;46:84–95.
- Fine HF, Zhitomirsky I, Freund KB, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina. 2009;29:8–12.
- Battaglia Parodi M, Iacono P, Kontadakis DS, et al. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. Arch Ophthalmol. 2010;128:1100–1103.
- Parodi MB, Iacono P, Mansour A, et al. Intravitreal bevacizumab for juxtafoveal choroidal neovascularization secondary to multifocal choroiditis. Retina. 2013;33:953–956.
- Cionni DA, Lewis SA, Petersen MR, et al. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis. Ophthalmology. 2012;119:327–332.
- Mirshahi A, Namavari S, Djalilian A, et al. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease. Ocul Immunol Inflamm. 2009;17:59–64.
- Mavrakanas N, Mendrinos E, Tabatabay C, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy. Acta Ophthalmol. 2010;88:e54–e55.
- Aoyagi R, Hayashi T, Masai A, et al. Subfoveal choroidal thickness in multiple evanescent white dot syndrome. Clin Exp Optom. 2012;95:212–217.